Clinical Research

A comparative study on spirometry and type 2 inflammatory markers in cough⁃variant asthma, asthma⁃COPD overlap, and classic asthma

  • Zhengzhang GUI ,
  • Lu YE ,
  • Yang ZHOU ,
  • Ling WANG ,
  • Yifeng JIN
Expand
  • Department of General Practice of the First Affiliated Hospital of Soochow University,Suzhou 215006,Jiangsu,China

Received date: 2025-03-29

  Online published: 2025-07-18

Abstract

Objective To analyze the characteristics of spirometry and type 2 inflammation indicators of patients with CVA, ACO and CA to determine their clinical utility in identifying and distinguishing among CVA, ACO and CA patients. Methods Clinical data from 483 patients diagnosed with bronchial asthma, CVA, and bronchial asthma combined with chronic obstructive pulmonary disease in the outpatient department of the First Affiliated Hospital of Soochow University from July 2023 to June 2024 were collected and divided into CA, CVA and ACO groups according to diagnosis. Comparison of spirometry, fractional exhaled nitric oxide (FeNO), blood eosinophil (EOS), serum total immunoglobulin E (tIgE) and other tests between CA and CVA, CA and ACO groups. Perform logistic regression analysis on significant test results, then construct receiver operating characteristic (ROC) curves to compare the area under the curve and corresponding cut-off values. Result There was a statistically significant difference in tIgE between the CVA and CA groups (P = 0.018), whereas no significant differences were observed in FeNO and EOS. Additionally, no notable differences were found between the ACO and CA groups in tIgE, FeNO, or EOS. Finally, FEV1%pred (OR = 1.086, P = 0.019), FEV1/FVC (OR = 1.153, P = 0.023), and MEF50%pred (OR = 0.922, P = 0.045) were used to construct the discriminative model between CA and CVA. ROC curves were plotted, with FEV1%pred showing an AUC of 0.680 (P < 0.001), a Youden index of 0.358, and a corresponding cutoff value of 89.200. FEV1/FVC had an AUC of 0.684 (P < 0.001), a Youden index of 0.334, and a cutoff value of 76.075. MEF50%pred had an AUC of 0.668 (P < 0.001), a Youden index of 0.309, and a cutoff value of 59.800. The combined sensitivity of these three measures was 0.909, specificity was 0.514, positive predictive value was 0.600, negative predictive value was 0.873, and the AUC was 0.773 (P < 0.001), with a Youden index of 0.423. FEV1 (OR = 0.002, P = 0.045), FEV1%pred (OR = 1.490, P = 0.006), and FEV1/FVC (OR = 0.749, P = 0.005) were used to construct the discriminative model between CA and ACO. ROC curves were plotted, with FEV1 showing an AUC of 0.819 (P < 0.001), a Youden index of 0.532, and a corresponding cutoff value of 2.060. FEV1%pred had an AUC of 0.788 (P < 0.001), a Youden index of 0.501, and a cutoff value of 75.000. FEV1/FVC had an AUC of 0.891 (P < 0.001), a Youden index of 0.678, and a cutoff value of 68.620. The combined sensitivity of these three measures was 1.000, specificity was 0.904, positive predictive value was 0.771, negative predictive value was 1.000, and the AUC was 0.973 (P < 0.001), with a Youden index of 0.904. Conclusions Differences exist in the spirometry among CVA, ACO and CA. The spirometry results incorporated into the discriminative models provide good discriminative value for distinguishing between CA and CVA patients with similar clinical symptoms, as well as for identifying ACO in the CA population.

Cite this article

Zhengzhang GUI , Lu YE , Yang ZHOU , Ling WANG , Yifeng JIN . A comparative study on spirometry and type 2 inflammatory markers in cough⁃variant asthma, asthma⁃COPD overlap, and classic asthma[J]. The Journal of Practical Medicine, 2025 , 41(13) : 2065 -2072 . DOI: 10.3969/j.issn.1006-5725.2025.13.018

References

[1] Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023[EB/OL]. (2023-07-06)[2025-03-29]. .
[2] HAMMAD H, LAMBRECHT B N. The basic immunology of asthma[J]. Cell, 2021,184(6):1469-1485. doi:10.1016/j.cell.2021.02.016
[3] 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版)[J]. 中华结核和呼吸杂志, 2020,43(12):1023-1048. doi:10.3760/cma.j.cn112147-20200618-00721
[4] 中华医学会呼吸病学分会哮喘学组. 咳嗽的诊断与治疗指南(2021)[J]. 中华结核和呼吸杂志, 2022,45(1):13-46.
[5] NAKAMURA Y, TAMAOKI J, NAGASE H, et al. Japanese guidelines for adult asthma 2020[J]. Allergol Int, 2020,69(4):519-548. doi:10.1016/j.alit.2020.08.001
[6] 中华医学会呼吸病学分会. 轻度支气管哮喘诊断与治疗中国专家共识(2023) [J]. 中华结核和呼吸杂志, 2023,46(9):880-896.
[7] 张明强,牟向东. 2型炎症型支气管哮喘的生物靶向治疗[J].新医学,2024,55(11):944-949.
[8] DE DIEGO A, MARTíNEZ E, PERPI?á M, et al. Airway inflammation and cough sensitivity in cough-variant asthma[J]. Allergy, 2005,60(11):1407-1411. doi:10.1111/j.1398-9995.2005.00609.x
[9] LAI K, ZHAN W, WU F, et al. Clinical and Inflammatory Characteristics of the Chinese APCA Cough Variant Asthma Cohort[J]. Front Med (Lausanne), 2022,8:807385. doi:10.3389/fmed.2021.807385
[10] DING B, DIBONAVENTURA M, KARLSSON N, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome in the urban Chinese population: prevalence and disease burden using the 2010, 2012, and 2013 China National Health and Wellness Surveys[J]. Int J Chron Obstruct Pulmon Dis, 2016,11:1139-1150. doi:10.2147/copd.s103873
[11] WHEATON A G, PLEASANTS R A, CROFT J B, et al. Gender and asthma-chronic obstructive pulmonary disease overlap syndrome[J]. J Asthma, 2016,53(7):720-731. doi:10.3109/02770903.2016.1154072
[12] LEUNG C, SIN D D. Asthma-COPD Overlap: What Are the Important Questions? [J] Chest, 2022,161(2):330-344. doi:10.1016/j.chest.2021.09.036
[13] Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024[EB/OL]. Available from: .
[14] 中国呼吸医师协会肺功能与临床呼吸生理工作委员会,中华医学会呼吸病学分会呼吸治疗学组. 肺功能检查报告规范——肺量计检查、支气管舒张试验、支气管激发试验[J]. 中华医学杂志, 2019,99(22):1681-1691.
[15] XIAO D, CHEN Z, WU S, et al. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study[J]. Lancet Respir Med, 2020,8(11):1081-1093.
[16] DE LLANO L P, COSíO B G, IGLESIAS A, et al. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach[J]. Int J Chron Obstruct Pulmon Dis, 2018,13:591-601. doi:10.2147/copd.s153694
[17] Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report)[J]. Am J Respir Crit Care Med, 2025, 187(4):347-365.
[18] KOH Y Y, JEONG J H, PARK Y, et al. Development of wheezing in patients with cough variant asthma during an increase in airway responsiveness[J]. Eur Respir J, 1999,14(2):302-308. doi:10.1034/j.1399-3003.1999.14b11.x
[19] LIU W, CHEN H, ZHANG D, et al. A retrospective study of clinical features of cough variant asthma in Chinese adults[J]. Allergy Asthma Clin Immunol, 2019,15:3. doi:10.1186/s13223-019-0318-5
[20] 中华医学会呼吸病学分会哮喘学组. 支气管激发试验临床应用中国专家共识(2024版)[J]. 中华医学杂志, 2024,104(22):2031-2040.
[21] GAO J, WU H, WU F. Small airway dysfunction in patients with cough variant asthma: A retrospective cohort study[J]. BMC Pulm Med, 2021,21(1):49. doi:10.1186/s12890-021-01419-4
[22] 中华医学会变态反应学分会. 2型炎症性疾病机制及靶向治疗专家共识[J]. 中华医学杂志, 2022,102(42):3349-3373.
[23] 缪晔红,沈莹莹,魏源,等. FeNO、外周血EOS计数及血清总IgE对支气管哮喘的联合诊断价值探讨[J]. 国际呼吸杂志, 2022,42(8):583-588.
[24] 张彩霞,王新卫,刘新年,等. 常规肺功能正常的咳嗽变异性哮喘特点[J]. 国际呼吸杂志, 2023,43(8):918-924.
[25] RAJEEV A, MATHAI S S, KULKARNI B. Use of exhaled nitric oxide in children with bronchial asthma[J]. Med J Armed Forces India, 2015,71(4):337-339. doi:10.1016/j.mjafi.2015.07.001
[26] DEY S, EAPEN M S, CHIA C, et al. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities[J]. Am J Physiol Lung Cell Mol Physiol, 2022,322(1):L64-L83. doi:10.1152/ajplung.00121.2021
[27] ALSHABANAT A, ZAFARI Z, ALBANYAN O, et al. Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis[J]. PLoS One, 2015,10(9):e0136065. doi:10.1371/journal.pone.0136065
[28] PAPAKONSTANTINOU E, SAVIC S, SIEBENEICHLER A, et al. A pilot study to test the feasibility of histological characterisation of asthma-COPD overlap[J]. Eur Respir J, 2019,53(6):1801941. doi:10.1183/13993003.01941-2018
[29] FOUKA E, PAPAIOANNOU A I, HILLAS G, et al. Asthma-COPD Overlap Syndrome: Recent Insights and Unanswered Questions[J]. J Pers Med, 2022,12(5):708. doi:10.3390/jpm12050708
[30] 李然,刘晓芳,王玉红,等. 肺功能在支气管哮喘、COPD及哮喘-COPD重叠中的差异性分析[J]. 国际呼吸杂志, 2021,41(19):1487-1492.
[31] USMANI O S, HAN M K, KAMINSKY D A, et al. Seven Pillars of Small Airways Disease in Asthma and COPD: Supporting Opportunities for Novel Therapies[J]. Chest, 2021,160(1):114-134. doi:10.1016/j.chest.2021.03.047
Outlines

/